Laymen's summary:
In this research, scientists explored whether individuals genetically predisposed to schizophrenia might require higher doses of antipsychotics or the use of multiple antipsychotic drugs, a practice known as antipsychotic polypharmacy, to treat psychotic disorders. The study analyzed data from five Nordic cohorts, totaling 21,572 individuals diagnosed with conditions such as schizophrenia and bipolar disorder. To evaluate genetic susceptibility to schizophrenia, the researchers utilized a polygenic risk score (PRS) — a tool that aggregates the effects of numerous genetic factors to estimate an individual's likelihood of developing a certain disease.
The findings indicated a significant association between a higher genetic risk for schizophrenia and the need for increased doses of antipsychotic medications. There was also a notable link to the requirement for antipsychotic polypharmacy. The uniformity of these results across different cohorts highlights the potential utility of genetic information in devising more personalised antipsychotic treatment plans for patients.
This study emphasises the potential of using real-world data to advance precision medicine initiatives in psychiatry. Precision medicine involves tailoring healthcare, with decisions and treatments adapted to the individual patient based on their specific genetic makeup and disease risk. The results suggest that by understanding a patient's genetic profile, healthcare providers can better determine the most suitable antipsychotic dosages and combinations, improving treatment efficacy and minimising side effects. This approach marks a significant leap towards more personalised care in mental health, indicating a promising future for the integration of genetic insights into psychiatric treatment strategies.
Access the article here.